Thermo Fisher Scientific Showcases Cell Reprogramming in Treatment-Resistant Prostate Cancer
Yorba Linda, Ca (PRWEB) August 16, 2017 -- Recent studies show that cancer cells can resist treatment by changing into a different cell type. Many treatments for specific cancers, such as breast, prostate, or lung, target vital pathways active in healthy tissue. A prominent example of targeted treatment is androgen deprivation therapy for advanced prostate cancer.
This therapy limits the production and effectiveness of androgen hormones because prostate cancer cells depend on androgen hormones, just like their healthy counterparts. Prostate cancers that become resistant to multiple rounds of therapy often no longer express the target of therapy. These resistant or ‘reprogrammed’ tumor cells are more likely to express different cell lineage markers.
In this webinar, participants will gain a better understanding of the benefits of 3D organoid culture on modeling cancer. They will also learn about prostate cancer cell reprogramming and how the understanding of this can lead to improved therapies.
Organoid culture is a valuable research tool, as it allows the formation of structures that include multiple cell types. In the future, laboratories could use organoids of aggressive prostate cancer in screens of drug candidates and assess drug effectiveness in weeks, rather than the months or years required for classic in vivo studies.
For this event, Thermo Fisher Scientific has arranged for Dr. Kristine Wadosky, a research affiliate at Roswell Park Cancer Institute, to be the speaker.
As an expert in prostate cancer research, Kristine received a bachelor of science in molecular genetics from the University of Rochester. She later went on to earn a doctorate in pathology at the University of North Carolina, where her research focused on protein degradation pathways in cardiac and skeletal muscle diseases. Recently, her study of thyroid hormone signaling in cardiac growth was awarded a Journal Award by the Society for Endocrinology for being one of the five best papers published by its journals in 2016.
LabRoots will host the event August 30, 2017, beginning at 10:00 a.m. PDT, 1:00 p.m. EDT. To read more about this event, discover what continuing education credits will be offered, or to register for free, click here.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit http://www.thermofisher.com.
About LabRoots
LabRoots is the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.
Karen Sorenson, LabRoots, Inc., http://www.LabRoots.com, +1 (619) 861-0590, [email protected]
Share this article